medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2006; 5 (1)


Hepatocellular carcinoma. An overview

Motola-Kuba D, Zamora-Valdés D, Uribe M, Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 58
Paginas: 16-24
Archivo PDF: 117.45 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. el-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 87–107, vi.

  2. Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol 2003; 19: 243–9.

  3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745–50.

  4. Horie Y, Yamagishi Y, Kajihara M, Kato S, Ishii H. National survey of hepatocellular carcinoma in heavy drinkers in Japan. Alcohol Clin Exp Res 2003; 27: 32S–6S.

  5. Uetake S, Yamauchi M, Itoh S, Kawashima O, Takeda K, Ohata M. Analysis of risk factors for hepatocellular carcinoma in patients with HBs antigen- and anti-HCV antibody-negative alcoholic cirrhosis: clinical significance of prior hepatitis B virus infection. Alcohol Clin Exp Res 2003; 27: 47S–51S.

  6. Goncalves CS, Pereira FE, Gayotto LC. Hepatocellular carcinoma in Brazil: report of a national survey (Florianopolis, SC, 1995). Rev Inst Med Trop Sao Paulo 1997; 39: 165–70.

  7. Cortes-Espinosa T, Mondragon-Sanchez R, Hurtado-Andrade H, Sanchez-Cisneros R. Hepatocellular carcinoma and hepatic cirrhosis in Mexico: a 25 year necroscopy review. Hepatogastroenterology 1997; 44: 1401–3.

  8. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, Martinez I, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37: 520–7.

  9. Bailey MA, Brunt EM. Hepatocellular carcinoma: predisposing conditions and precursor lesions. Gastroenterol Clin North Am 2002; 31: 641–62.

  10. Mendez-Sanchez N, Aguilar-Ramirez JR, Reyes A, Dehesa M, Juorez A, Castaneda B, Sanchez-Avila F, et al. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004; 3: 30–3.

  11. Mendez-Sanchez N, Villa AR, Chavez-Tapia NC, Ponciano-Rodriguez G, Almeda-Valdes P, Gonzalez D, Uribe M. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 4: 52–5.

  12. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 2005; 25: 16–27.

  13. Hytiroglou P. Morphological changes of early human hepatocarcinogenesis. Semin Liver Dis 2004; 24: 65–75.

  14. Borzio M, Fargion S, Borzio F, Fracanzani AL, Croce AM, Stroffolini T, Oldani S, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003; 39: 208–14.

  15. Kaplan DE, Reddy KR. Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes. Clin Liver Dis 2003; 7: 683–714.

  16. Zein NN, Poterucha JJ, Gross JB, Jr., Wiesner RH, Therneau TM, Gossard AA, Wendt NK, et al. Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1b. Am J Gastroenterol 1996; 91: 2560–2.

  17. Tarao K, Rino Y, Ohkawa S, Tamai S, Miyakawa K, Takakura H, Endo O, et al. Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis. Cancer 2002; 94: 1787–95.

  18. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191–211, v.

  19. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429–31.

  20. Lee YI, Lee S, Das GC, Park US, Park SM. Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma. Oncogene 2000; 19: 3717–26.

  21. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, Fargion S. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001; 33: 647–51.

  22. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269: 15957–60.

  23. Parmar JS, Lomas DA. Alpha-1-antitrypsin deficiency, the serpinopathies and conformational disease. J R Coll Physicians Lond 2000; 34: 295–300.

  24. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434–8.

  25. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112–7.

  26. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513–7.

  27. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664–9.

  28. Mendez-Sanchez N, Sanchez-Castillo CP, Villa AR, Madrigal H, Merino B, Garcia E, Lopez P, et al. The relationship of overweight and obesity to high mortality rates from liver cirrhosis in Mexico. Ann Hepatol 2004; 3: 66–71.

  29. Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–38.

  30. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134–40.

  31. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485–93.

  32. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36: 150–5.

  33. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis 1999; 19: 235–42.

  34. Macdonald GA. Pathogenesis of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 69–85.

  35. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999; 353: 1253–7.

  36. Sohara N, Takagi H, Yamada T, Ichikawa T, Abe T, Itoh H, Mori M. Esophageal metastasis of hepatocellular carcinoma. Gastrointest Endosc 2000; 51: 739–41.

  37. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122: 1609–19.

  38. Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52 Suppl 3: iii1–8.

  39. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 145–59.

  40. Weissenberger C, Fiebig HH, Lutterbach J, Barke A, Momm F, Muller M, Witucki G, et al. Is there any correlation between MDR1, GST-pi-expression and CEA? Anticancer Res 2000; 20: 5139–44.

  41. Taheri M, Saragovi U, Fuks A, Makkerh J, Mort J, Stanners CP. Self recognition in the Ig superfamily. Identification of precise subdomains in carcinoembryonic antigen required for intercellular adhesion. J Biol Chem 2000; 275: 26935–43.

  42. Shouval D. HCC: what’s the score? Gut 2002; 50: 749–50.

  43. Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002; 50: 881–5.

  44. Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, Baba Y, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 2001; 34: 529–34.

  45. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54: 411–8.

  46. Aguayo A, Patt YZ. Nonsurgical treatment of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 175–89.

  47. Geschwind JF, Ramsey DE, Choti MA, Thuluvath PJ, Huncharek MS. Chemoembolization of hepatocellular carcinoma: results of a metaanalysis. Am J Clin Oncol 2003; 26: 344–9.

  48. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174–81.

  49. Rust C, Gores GJ. Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies. Clin Liver Dis 2001; 5: 161–73.

  50. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–9.

  51. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519–24.

  52. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434–40.

  53. Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, Visa J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018–22.

  54. Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, Sakamoto M, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994; 106: 1618–24.

  55. Yamasaki S, Hasegawa H, Kinoshita H, Furukawa M, Imaoka S, Takasaki K, Kakumoto Y, et al. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 1996; 87: 206–11.

  56. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, Denys A, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003; 237: 208–17.

  57. Bruix J and Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208–36.

  58. Olthoff KM, Rosove MH, Shackleton CR, Imagawa DK, Farmer DG, Northcross P, Pakrasi AL, et al. Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg 1995; 221: 734–41; discussion 14.




2020     |     www.medigraphic.com